vs
AvePoint（AVPT）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是AvePoint的1.8倍（$207.3M vs $114.7M），AvePoint净利率更高（13.6% vs -62.0%，领先75.7%），AvePoint同比增速更快（28.6% vs 25.9%），AvePoint自由现金流更多（$29.0M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 24.0%）
AvePoint是一家总部位于美国新泽西州泽西市的企业，成立于2001年，2020年在纳斯达克上市。公司专注于开发软件产品，为Microsoft 365、谷歌、Salesforce等主流平台提供功能拓展与安全增强解决方案，服务全球各行业客户的数字化协作与数据治理需求。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
AVPT vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $114.7M | $207.3M |
| 净利润 | $15.6M | $-128.6M |
| 毛利率 | 73.6% | — |
| 营业利润率 | 12.7% | -54.7% |
| 净利率 | 13.6% | -62.0% |
| 营收同比 | 28.6% | 25.9% |
| 净利润同比 | 191.1% | 3.5% |
| 每股收益（稀释后） | $0.06 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $114.7M | $207.3M | ||
| Q3 25 | $109.7M | $159.9M | ||
| Q2 25 | $102.0M | $166.5M | ||
| Q1 25 | $93.1M | $139.3M | ||
| Q4 24 | $89.2M | $164.6M | ||
| Q3 24 | $88.8M | $139.5M | ||
| Q2 24 | $78.0M | $147.0M | ||
| Q1 24 | $74.5M | $108.8M |
| Q4 25 | $15.6M | $-128.6M | ||
| Q3 25 | $13.0M | $-180.4M | ||
| Q2 25 | $2.9M | $-115.0M | ||
| Q1 25 | $3.6M | $-151.1M | ||
| Q4 24 | $-17.2M | $-133.2M | ||
| Q3 24 | $2.6M | $-133.5M | ||
| Q2 24 | $-12.9M | $-131.6M | ||
| Q1 24 | $-2.0M | $-170.7M |
| Q4 25 | 73.6% | — | ||
| Q3 25 | 74.4% | — | ||
| Q2 25 | 74.0% | — | ||
| Q1 25 | 74.3% | — | ||
| Q4 24 | 75.4% | — | ||
| Q3 24 | 76.1% | — | ||
| Q2 24 | 75.7% | — | ||
| Q1 24 | 72.6% | — |
| Q4 25 | 12.7% | -54.7% | ||
| Q3 25 | 7.4% | -106.9% | ||
| Q2 25 | 7.0% | -64.8% | ||
| Q1 25 | 3.5% | -102.6% | ||
| Q4 24 | 5.4% | -74.3% | ||
| Q3 24 | 8.6% | -94.6% | ||
| Q2 24 | -2.7% | -79.1% | ||
| Q1 24 | -4.3% | -151.9% |
| Q4 25 | 13.6% | -62.0% | ||
| Q3 25 | 11.9% | -112.8% | ||
| Q2 25 | 2.8% | -69.0% | ||
| Q1 25 | 3.8% | -108.5% | ||
| Q4 24 | -19.3% | -80.9% | ||
| Q3 24 | 3.0% | -95.7% | ||
| Q2 24 | -16.6% | -89.5% | ||
| Q1 24 | -2.6% | -156.8% |
| Q4 25 | $0.06 | $-1.28 | ||
| Q3 25 | $0.06 | $-1.81 | ||
| Q2 25 | $0.01 | $-1.17 | ||
| Q1 25 | $0.02 | $-1.57 | ||
| Q4 24 | $-0.09 | $-1.34 | ||
| Q3 24 | $0.01 | $-1.40 | ||
| Q2 24 | $-0.07 | $-1.52 | ||
| Q1 24 | $-0.01 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $481.1M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $478.7M | $-80.0M |
| 总资产 | $789.2M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $481.1M | $421.0M | ||
| Q3 25 | $471.6M | $202.5M | ||
| Q2 25 | $430.1M | $176.3M | ||
| Q1 25 | $351.8M | $127.1M | ||
| Q4 24 | $290.9M | $174.0M | ||
| Q3 24 | $250.0M | $150.6M | ||
| Q2 24 | $230.8M | $480.7M | ||
| Q1 24 | $219.3M | $112.3M |
| Q4 25 | $478.7M | $-80.0M | ||
| Q3 25 | $466.8M | $9.2M | ||
| Q2 25 | $443.1M | $151.3M | ||
| Q1 25 | $361.5M | $144.2M | ||
| Q4 24 | $270.9M | $255.0M | ||
| Q3 24 | $215.7M | $346.8M | ||
| Q2 24 | $207.4M | $432.4M | ||
| Q1 24 | $212.7M | $140.3M |
| Q4 25 | $789.2M | $1.5B | ||
| Q3 25 | $743.5M | $1.2B | ||
| Q2 25 | $700.1M | $1.3B | ||
| Q1 25 | $598.8M | $1.3B | ||
| Q4 24 | $519.1M | $1.5B | ||
| Q3 24 | $463.0M | $1.5B | ||
| Q2 24 | $427.3M | $1.6B | ||
| Q1 24 | $413.8M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $29.7M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $29.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | 25.3% | -48.6% |
| 资本支出强度资本支出/营收 | 0.6% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.90× | — |
| 过去12个月自由现金流最近4个季度 | $81.6M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $29.7M | $-99.8M | ||
| Q3 25 | $34.8M | $-91.4M | ||
| Q2 25 | $20.3M | $-108.3M | ||
| Q1 25 | $495.0K | $-166.5M | ||
| Q4 24 | $32.8M | $-79.3M | ||
| Q3 24 | $32.2M | $-67.0M | ||
| Q2 24 | $16.2M | $-77.0M | ||
| Q1 24 | $7.8M | $-190.7M |
| Q4 25 | $29.0M | $-100.8M | ||
| Q3 25 | $34.3M | $-92.7M | ||
| Q2 25 | $19.3M | $-110.7M | ||
| Q1 25 | $-1.0M | $-167.8M | ||
| Q4 24 | $32.0M | $-79.5M | ||
| Q3 24 | $30.8M | $-68.6M | ||
| Q2 24 | $15.8M | $-79.0M | ||
| Q1 24 | $7.3M | $-193.9M |
| Q4 25 | 25.3% | -48.6% | ||
| Q3 25 | 31.3% | -58.0% | ||
| Q2 25 | 18.9% | -66.5% | ||
| Q1 25 | -1.1% | -120.5% | ||
| Q4 24 | 35.9% | -48.3% | ||
| Q3 24 | 34.7% | -49.2% | ||
| Q2 24 | 20.2% | -53.7% | ||
| Q1 24 | 9.7% | -178.2% |
| Q4 25 | 0.6% | 0.5% | ||
| Q3 25 | 0.5% | 0.8% | ||
| Q2 25 | 0.9% | 1.5% | ||
| Q1 25 | 1.6% | 1.0% | ||
| Q4 24 | 0.8% | 0.1% | ||
| Q3 24 | 1.6% | 1.2% | ||
| Q2 24 | 0.5% | 1.4% | ||
| Q1 24 | 0.7% | 3.0% |
| Q4 25 | 1.90× | — | ||
| Q3 25 | 2.68× | — | ||
| Q2 25 | 7.01× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 12.30× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVPT
| SAAS | $88.9M | 78% |
| Services | $14.7M | 13% |
| Termed License And Support | $10.1M | 9% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
